AbbVie Inc. (NYSE:ABBV) is Guardian Investment Management's 8th Largest Position

Guardian Investment Management reduced its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 7.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,400 shares of the company's stock after selling 1,401 shares during the quarter. AbbVie makes up approximately 2.8% of Guardian Investment Management's investment portfolio, making the stock its 8th biggest position. Guardian Investment Management's holdings in AbbVie were worth $3,436,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Crestline Management LP boosted its stake in AbbVie by 438.4% during the fourth quarter. Crestline Management LP now owns 35,311 shares of the company's stock valued at $6,275,000 after buying an additional 28,753 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of AbbVie by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 9,367,162 shares of the company's stock worth $1,664,489,000 after acquiring an additional 108,993 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of AbbVie by 35.8% during the 4th quarter. Quantbot Technologies LP now owns 1,047 shares of the company's stock valued at $186,000 after acquiring an additional 276 shares during the last quarter. AXA S.A. grew its holdings in shares of AbbVie by 14.8% in the fourth quarter. AXA S.A. now owns 971,893 shares of the company's stock valued at $172,705,000 after purchasing an additional 125,568 shares in the last quarter. Finally, Highland Capital Management LLC grew its holdings in shares of AbbVie by 6.3% in the first quarter. Highland Capital Management LLC now owns 46,853 shares of the company's stock valued at $9,817,000 after purchasing an additional 2,792 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

ABBV traded up $4.30 on Tuesday, reaching $189.92. 5,936,750 shares of the company's stock were exchanged, compared to its average volume of 6,249,200. AbbVie Inc. has a twelve month low of $163.52 and a twelve month high of $218.66. The stock has a market cap of $335.47 billion, a PE ratio of 80.82, a P/E/G ratio of 1.21 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The stock's fifty day moving average price is $186.52 and its 200-day moving average price is $188.21.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. During the same quarter last year, the firm earned $2.31 EPS. The business's revenue was up 8.4% compared to the same quarter last year. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date is Tuesday, July 15th. AbbVie's payout ratio is 279.15%.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABBV. Evercore ISI increased their price objective on shares of AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Cantor Fitzgerald assumed coverage on shares of AbbVie in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $210.00 price target for the company. BNP Paribas upgraded AbbVie to a "hold" rating in a research report on Thursday, May 8th. Bank of America boosted their price objective on AbbVie to $204.00 and gave the stock a "hold" rating in a research note on Monday, June 9th. Finally, Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a research report on Monday, March 17th. Eight equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $211.29.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.